Sustained reduction in circulating cholesterol in adult hypopituitary patients given low dose titrated growth hormone replacement therapy: a two year study.

Sustained reduction in circulating cholesterol in adult hypopituitary patients given low dose titrated growth hormone replacement therapy: a two year study.

OBJECTIVE: To study the effects of short (6 months) and longer-term (up to 24 months) growth hormone (GH) replacement therapy using a dose titration regimen, on lipid and glucose metabolism in GH-deficient, hypopituitary adults. DESIGN: On-going open study of GH treatment up to 24 months. Measureme...

Full description

Bibliographic Details
Main Authors:	Florakis, D, Hung, V, Kaltsas, G, Coyte, D, Jenkins, P, Chew, S, Grossman, AB, Besser, G, Monson, J
Format:	Journal article
Language:	English
Published:	2000

Similar Items

Comments on 'Sustained reduction in circulating cholesterol in adult hypopituitary patients given low dose titrated growth hormone replacement therapy: a two-year study' by Florakis et al (2000) - Reply
by: Monson, J, et al.
Published: (2001)

Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults.
by: Drake, WM, et al.
Published: (1998)

Growth hormone replacement does not increase serum prostate-specific antigen in hypopituitary men over 50 years.
by: le Roux, C, et al.
Published: (2002)

Unmasking of central hypothyroidism following growth hormone replacement in adult hypopituitary patients.
by: Agha, A, et al.
Published: (2007)

Hypothalamo-pituitary surveillance imaging in hypopituitary patients receiving long-term GH replacement therapy.
by: Frajese, G, et al.
Published: (2001)

Role of fasting plasma glucose, glycated haemoglobin and homeostatic model assessment in the detection of glucose intolerance in adult hypopituitary patients during growth hormone replacement therapy.
by: Colson, A, et al.
Published: (2008)

Safety of GH replacement in hypopituitary patients with nonirradiated pituitary and peripituitary tumours.
by: Chung, T, et al.
Published: (2008)

Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration.
by: Jenkins, P, et al.
Published: (2000)

Predictors of the outcome of surgical treatment in acromegaly and the value of the mean growth hormone day curve in assessing postoperative disease activity.
by: Kaltsas, G, et al.
Published: (2001)

Circulating Levels of Irisin in Hypopituitary and Normal Subjects.
by: Lara Pena-Bello, et al.
Published: (2016-01-01)

The effect of growth hormone (GH) replacement therapy on sympathetic nerve hyperactivity in hypopituitary adults: a double-blind, placebo-controlled, crossover, short-term trial followed by long-term open GH replacement in hypopituitary adults.
by: Sverrisdóttir, Y, et al.
Published: (2003)

Tumour surveillance imaging in patients with extrapituitary tumours receiving growth hormone replacement.
by: Chung, T, et al.
Published: (2005)

The modulation of platelet function by growth hormone in growth hormone deficient Hypopituitary patients
by: Irene K Oglesby, et al.
Published: (2023-09-01)

Growth hormone deficiency and replacement in patients with treated Cushing's Disease, prolactinomas and non-functioning pituitary adenomas: effects on body composition, glucose metabolism, lipid status and bone mineral density.
by: Colson, A, et al.
Published: (2006)

Discriminatory value of the low-dose dexamethasone suppression test in establishing the diagnosis and differential diagnosis of Cushing's syndrome.
by: Isidori, A, et al.
Published: (2003)

Classic cardiovascular risk factors improve in very elderly hypopituitary patients treated on standard hormone replacement in long term follow- up
by: Isabella Naves Rosa, et al.
Published: (2021-03-01)

Authors' response: The value of the low-dose dexamethasone suppression test in the differential diagnosis of hyperandrogenism in women
by: Kaltsas, G, et al.
Published: (2003)

The value of the low-dose dexamethasone suppression test in the differential diagnosis of hyperandrogenism in women.
by: Kaltsas, G, et al.
Published: (2003)

Prevalence and risk factors of the metabolic syndrome in young adults with childhood-onset hypopituitary growth hormone deficiency
by: Han Hyuk Lim, et al.
Published: (2010-10-01)

Uterine leiomyomata in women with acromegaly
by: Kaltsas, G, et al.
Published: (2000)

The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumors.
by: Kaltsas, G, et al.
Published: (1998)

Male-female differences in 6-sulfatoxymelatonin excretion in hypopituitary patients
by: Hugo L. Fideleff, et al.
Published: (2016-02-01)

Alterations in serum protein levels in patients with Cushing's syndrome before and after successful treatment.
by: Putignano, P, et al.
Published: (2000)

Hypothalamo-pituitary abnormalities in adult patients with langerhans cell histiocytosis: clinical, endocrinological, and radiological features and response to treatment.
by: Kaltsas, G, et al.
Published: (2000)

The prevalence and characteristic features of cyclicity and variability in Cushing's disease.
by: Alexandraki, K, et al.
Published: (2009)

The growth hormone secretagogue hexarelin stimulates the hypothalamo-pituitary-adrenal axis via arginine vasopressin.
by: Korbonits, M, et al.
Published: (1999)

Hexarelin as a test of pituitary reserve in patients with pituitary disease.
by: Korbonits, M, et al.
Published: (1999)

Growth hormone cut-off post glucagon stimulation test in an Indian cohort of overweight/obese hypopituitary patients for the diagnosis of adult growth hormone deficiency
by: Vijay Sheker Reddy Danda, et al.
Published: (2023-01-01)

Calcium and calmodulin mediation of growth hormone-releasing hormone release from the rat hypothalamus in vitro.
by: Honegger, J, et al.
Published: (1991)

Menstrual irregularity in women with acromegaly.
by: Kaltsas, G, et al.
Published: (1999)

Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors.
by: Kaltsas, G, et al.
Published: (2001)

Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG].
by: Mukherjee, J, et al.
Published: (2001)

Secondary forms of polycystic ovary syndrome.
by: Kaltsas, G, et al.
Published: (2004)

Growth hormone releasing hormone.
by: Grossman, A, et al.
Published: (1986)

Successful treatment of childhood-onset Cushing's disease is associated with persistent reduction in growth hormone secretion.
by: Carroll, P, et al.
Published: (2004)

Clinical and biochemical characteristics of adrenocorticotropin-secreting macroadenomas.
by: Woo, Y, et al.
Published: (2005)

Pyridostigmine partially reverses dexamethasone-induced inhibition of the growth hormone response to growth hormone-releasing hormone.
by: Trainer, P, et al.
Published: (1992)

How common are polycystic ovaries and the polycystic ovarian syndrome in women with Cushing's syndrome?
by: Kaltsas, G, et al.
Published: (2000)

Treatment of advanced neuroendocrine tumours using combination chemotherapy with lomustine and 5-fluorouracil.
by: Kaltsas, G, et al.
Published: (2002)

Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group.
by: Tomlinson, J, et al.
Published: (2001)